GlassScriptPhysician profile
Moira E Wristen
NPI 1689653024
$4,811.03
in general payments reported to CMS, 2019-2025
33 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $550 · 2024: $1,972 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $960.84 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $635.06 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $628.05 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $526.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $284.67 | 2023-2025 | Tavneos, Repatha, Otezla |
| Lilly USA, LLC | $262.82 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $251.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $119.66 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Stryker Corporation | $109.50 | 2025 | Flowtriever |
| Phathom Pharmaceuticals, INC. | $107.52 | 2024-2025 | Voquezna |
| Abbott Laboratories | $104.98 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.89 | 2023-2025 | Jardiance |
| Nevro Corp. | $88.19 | 2023-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.37 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $62.76 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $61.92 | 2025 | |
| Astellas Pharma US INC | $59.06 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $41.14 | 2024-2025 | Gvoke Hypopen |
| Eisai INC. | $38.31 | 2024-2025 | |
| Protega Pharmaceutials INC | $35.19 | 2024 | Roxybond |
| Bayer Healthcare Pharmaceuticals INC. | $32.02 | 2024-2025 | |
| Ardelyx, INC. | $31.89 | 2025 | Ibsrela |
| Amneal Pharmaceuticals LLC | $30.61 | 2024 | Unithroid, Rytary |
| Soleno Therapeutics, INC. | $20.98 | 2025 | Vykat Xr |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Auvelity |
| Insulet Corporation | $20.06 | 2023 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.44 | 2025 | Caplyta |
| Globus Medical, INC. | $17.82 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $16.96 | 2024 | |
| Teleflex LLC | $16.76 | 2025 | Barrigel |
| Averitas Pharma INC. | $16.32 | 2024 | Qutenza |
| Esperion Therapeutics, INC. | $14.87 | 2025 | Nexletol |
| Nestle Healthcare Nutrition INC. | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moira Wristen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.